Mometasone
From Anvita Health Wiki
Contents |
Introduction
- Tradename: Elocon, Asmanex. Topical (Elocon), Inhaled glucocorticoid (Asmanex).
Indications
- maintenance prophylactic treatment of asthma in patients 12 years or older
Contraindications
- acute episodes of asthma, including status asthmaticus
- acute episodes of asthma, including status asthmaticus
Dosage
- start 220 ug (1 inhalation) QHS
- 440 ug (2 inhalations) BID if on oral glucocorticoid
- maximum 440 ug QD
- 880 ug QD if on oral glucocorticoid
- 'Twisthaler' device contains 30, 60 or 120 inhalations delivers 200 ug of mometasone furoate from the mouthpiece
- Nasonex nasal spray 1-2 whiffs QD
Pharmacokinetics
- maximum benefit may take 2 weeks or longer
- maximum benefit may take 2 weeks or longer
Adverse-effects
- generally mild to moderate in severity
- pharyngitis (8-13% vs 7% with placebo)
- upper respiratory tract infections (8-5% vs 7% with placebo)
- oral candidiasis (4-6% vs 2% with placebo)
- growth suppression & decreased bone mineral density has been reported
- drug adverse effects of glucocorticoids
- drug adverse effects of immunosuppressive agents
Drug-interactions
- no significant drug interactions in clinical trials
- drug interaction(s) of glucocorticoids with warfarin
- no significant drug interactions in clinical trials
Mechanism-of-action
- inhaled glucocorticoid The average wholesale price is $155.75/120 inhalations. (2005)
More General Terms
Internet Database
PubChem: 123620
PubChem: 441335
PubChem: 441336
PubChem: 55188
PubChem: 4240
References
- The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996.
- Prescriber's Letter 12(9): 2005 Asmanex (Mometasone Furoate Inhalation Powder) Detail-Document#: [1] (subscription needed) [2]
- Department of Veterans Affairs, VA National Formulary
